Kyle R. Jackson

Kyle R. Jackson

Auto-generated profile, based on publicly available information

Kyle R. Jackson

Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2018 in Annals of Surgery
Verified
Journal Article
Closed access
XMXavier Muller
Xavier Muller
FMFrancesca Marcon
Francesca Marcon
GSGonzalo Sapisochin
Gonzalo Sapisochin
MMMax Marquez
Max Marquez
FDFederica Dondero
Federica Dondero
PCPierre-Alain Clavien
Pierre-Alain Clavien
This multicentric study of 17 high-volume centers presents 12 benchmark values for liver transplantation. Those values, mostly targeting markers of morbidity, were gathered from 2024 “low risk” cases, and may serve as reference to assess outcome of single or any groups of patients. To propose benchmark outcome values in liver transplantation, serving as reference for assessing individual patients or any other patient groups. Best achievable results in liver transplantation, that is, benchmarks, are unknown. Consequently, outcome comparisons within or across centers over time remain speculative. Out of 7492 liver transplantation performed in 17 international centers from 3 continents, we identified 2024 low risk adult cases with a laboratory model for end-stage liver disease score ≤20 points, a balance of risk score ≤9, and receiving a primary graft by donation after brain death. We chose clinically relevant endpoints covering intra- and postoperative course, with a focus on complications graded by severity including the complication comprehensive index (CCI®). Respective benchmarks were derived from the median value in each center, and the 75 percentile was considered the benchmark cutoff. Benchmark cases represented 8% to 49% of cases per center. One-year patient-survival was 91.6% with 3.5% retransplantations. Eighty-two percent of patients developed at least 1 complication during 1-year follow-up. Biliary complications occurred in one-fifth of the patients up to 6 months after surgery. Benchmark cutoffs were ≤4 days for ICU stay, ≤18 days for hospital stay, ≤59% for patients with severe complications (≥ Grade III) and ≤42.1 for 1-year CCI®. Comparisons with the next higher risk group (model for end stage liver disease 21–30) disclosed an increase in morbidity but within benchmark cutoffs for most, but not all indicators, while in patients receiving a second graft from 1 center (n = 50) outcome values were all outside of benchmark values. Despite excellent 1-year survival, morbidity in benchmark cases remains high with half of patients developing severe complications during 1-year follow-up. Benchmark cutoffs targeting morbidity parameters offer a valid tool to assess higher risk groups.

10 May 2020 in American Journal of Transplantation
Verified
Journal Article
Open access
BBBrian J. Boyarsky
Brian J. Boyarsky
TCTeresa Po-Yu Chiang
Teresa Po-Yu Chiang
WWWilliam Werbel
William Werbel
CDChristine M. Durand
Christine M. Durand
RARobin K. Avery
Robin K. Avery
JGJacqueline M. Garonzik-Wang
Jacqueline M. Garonzik-Wang
COVID-19 is a novel, rapidly changing pandemic: consequently, evidence-based recommendations in solid organ transplantation (SOT) remain challenging and unclear. To understand the impact on transplant activity across the United States, and center-level variation in testing, clinical practice, and policies, we conducted a national survey between March 24, 2020 and March 31, 2020 and linked responses to the COVID-19 incidence map. Response rate was a very high 79.3%, reflecting a strong national priority to better understand COVID-19. Complete suspension of live donor kidney transplantation was reported by 71.8% and live donor liver by 67.7%. While complete suspension of deceased donor transplantation was less frequent, some restrictions to deceased donor kidney transplantation were reported by 84.0% and deceased donor liver by 73.3%; more stringent restrictions were associated with higher regional incidence of COVID-19. Shortage of COVID-19 tests was reported by 42.5%. Respondents reported a total of 148 COVID-19 recipients from 10 years posttransplant: 69.6% were kidney recipients, and 25.0% were critically ill. Hydroxychloroquine (HCQ) was used by 78.1% of respondents; azithromycin by 46.9%; tocilizumab by 31.3%, and remdesivir by 25.0%. There is wide heterogeneity in center-level response across the United States; ongoing national data collection, expert discussion, and clinical studies are critical to informing evidence-based practices.

23 June 2018 in American Journal of Transplantation
Verified
Journal Article
Open access
PDF file
SBSunjae Bae
Sunjae Bae
AMAllan B. Massie
Allan B. Massie
ATAlvin G. Thomas
Alvin G. Thomas
GBGahyun Bahn
Gahyun Bahn
XLXun Luo
Xun Luo
JWJacqueline M. Garonzik Wang
Jacqueline M. Garonzik Wang
The impact of donor quality on post‐kidney transplant (KT) survival may vary by candidate condition. Characterizing this variation would increase access to KT without sacrificing outcomes. We developed a tool to estimate post‐KT survival for combinations of donor quality and candidate condition. We studied deceased‐donor KT recipients (N=120,818) and waitlisted candidates (N=376,272) between 2005 and 2016 using the Scientific Registry of Transplant Recipients. Donor quality and candidate condition were measured using Kidney Donor Profile Index (KDPI) and Estimate Post‐Transplant Survival (EPTS). We estimated 5‐year post‐KT survival by combinations of KDPI and EPTS using random forests, and waitlist survival by EPTS using Weibull regressions. Survival benefit was defined as absolute reduction in mortality risk with KT. For candidates with EPTS=80, 5‐year waitlist survival was 47.6%, and 5‐year post‐KT survival was 78.9% after receiving kidneys with KDPI=20 and 70.7% with KDPI=80. The impact of KDPI on survival benefit varied greatly by EPTS. For candidates with low EPTS (e.g.40), survival benefit decreased with higher KDPI, but was still substantial even with KDPI=100 (>16 percentage‐points). Our prediction tool (www.transplantmodels.com/kdpi-epts) can support individualized decision‐making on kidney offers in clinical practice.

29 October 2018 in American Journal of Transplantation
Verified
Journal Article
Open access
PDF file
KJKyle R. Jackson
Kyle R. Jackson
KCKarina Covarrubias
Karina Covarrubias
CHCourtenay M. Holscher
Courtenay M. Holscher
XLXun Luo
Xun Luo
JCJennifer Chen
Jennifer Chen
JGJacqueline Garonzik-Wang
Jacqueline Garonzik-Wang
Deceased donor kidney transplantation (DDKT) rates for highly sensitized (HS) candidates increased early after implementation of the Kidney Allocation System (KAS) in 2014. However, this may represent a bolus effect, and a granular investigation of the current state of DDKT for HS candidates remains lacking. We studied 270,722 DDKT candidates from the SRTR from 12/4/2011–12/3/2014 (‘pre‐KAS’) and 12/4/2014–12/3/2017 (‘post‐KAS’), analyzing DDKT rates for HS candidates using adjusted negative binomial regression. Post‐KAS, candidates with the highest levels of sensitization had an increased DDKT rate compared to pre‐KAS (cPRA 98% adjusted incidence rate ratio [aIRR]:1.271.772.46 p=0.001, cPRA 99% aIRR:3.184.365.98 p<0.001, cPRA 99.5‐99.9% aIRR:16.9124.2934.89 p<0.001, and cPRA 99.9%+ aIRR:8.7911.5815.26 p<0.001). To determine whether these changes produced more equitable access to DDKT, we compared DDKT rates of HS to non‐HS candidates (cPRA 0‐79%). Post‐KAS, cPRA 98% candidates had an equivalent DDKT rate (aIRR:0.650.941.36, p=0.8) to non‐HS candidates, whereas 99% candidates had a higher DDKT rate (aIRR:1.191.682.38, p=0.02). Although cPRA 99.5‐99.9% candidates had an increased DDKT rate (aIRR:2.463.504.98, p<0.001) compared to non‐HS candidates, cPRA 99.9%+ candidates had a significantly lower DDKT rate (aIRR:0.290.400.56, p<0.001). KAS has improved access to DDKT for HS candidates, although substantial imbalance exists between cPRA 99.5‐99.9% and 99.9%+ candidates.

16 March 2010 in Developmental Dynamics
Verified
Journal Article
Open access
PDF file
CSChristina M. Shoemaker‐Daly
Christina M. Shoemaker‐Daly
KJKyle Jackson
Kyle Jackson
RYRyohei Yatsu
Ryohei Yatsu
YMYuiko Matsumoto
Yuiko Matsumoto
DCDavid Crews
David Crews
In reptiles with temperature‐dependent sex determination, gonadogenesis is initially directed by the incubation temperature of the egg during the middle third of embryonic development. The mechanism by which temperature is transduced into a sex‐determining molecular signal remains a mystery, and here we examine the molecular network underlying sex determination in gonads in vitro. We use a whole organ culture system to show that expression of putative members of the sex‐determining network (Dmrt1, Sox9, Mis, and FoxL2) are regulated by temperature endogenously within cells in the bipotential gonad and do not require other embryonic tissues to be expressed in a normal pattern in the red‐eared slider turtle, Trachemys scripta. Furthermore, following a change in temperature, these factors exhibit temperature‐responsive expression patterns that last for the duration of gonadogenesis. Finally, mosaic misexpression of a fusion Sox9 construct demonstrates the ability to functionally manipulate the gonad at the molecular level. Developmental Dynamics 239:1061–1075, 2010.

7 June 2020 in American Journal of Transplantation
Verified
Journal Article
Open access
PDF file
KJKyle R. Jackson
Kyle R. Jackson
JMJennifer D. Motter
Jennifer D. Motter
SBSunjae Bae
Sunjae Bae
AKAmber Kernodle
Amber Kernodle
JLJane J. Long
Jane J. Long
DSDorry Segev
Dorry Segev
Infections remain a major threat to successful kidney transplantation (KT). To characterize the landscape and impact of post‐KT infections in the modern era, we used United States Renal Data System data linked to Scientific Registry of Transplant Recipients to study 141,661 Medicare‐primary KT recipients from 1/1/1999‐12/31/2014. Infection diagnoses were ascertained by ICD‐9 codes. The cumulative incidence of a post‐KT infection was 36.9% at 3 months, 53.7% at 1 year, and 78.0% at 5 years. The most common infections were UTI (46.8%) and pneumonia (28.2%). 5‐year mortality for KT recipients who developed an infection was 24.9% vs. 7.9% for those who did not, and 5‐year death‐censored graft failure (DCGF) was 20.6% vs. 10.1% (p<0.001). This translated to a 2.22‐fold higher mortality risk (adjusted hazard ratio [aHR]: 2.152.222.29, p<0.001) and 1.92‐fold higher DCGF risk (aHR: 1.841.911.98, p<0.001) for KT recipients who developed an infection, although the magnitude of this higher risk varied across infection types (for example, 3.11‐fold higher mortality risk for sepsis versus 1.62‐fold for a UTI). Post‐KT infections are common and substantially impact mortality and DCGF, even in the modern era. KT recipients at high risk for infections might benefit from enhanced surveillance or follow‐up to mitigate these risks.